氯沙坦钾和吲达帕胺缓释片治疗慢性心衰临床观察

Clinical observation of treatment for congestive heart failure with losartanK and indapamide SR

目的研究氯沙坦钾和吲达帕胺缓释片对慢性充血性心衰(CHF)治疗的临床疗效及安全性影响。方法选择59例无休克,无严重肝肾功能不全,无低钾血症的CHF患者,在基础治疗同时,予氯沙坦钾50mg/d,吲达帕胺缓释片1.5mg/d,治疗16周,治疗前后测血压、心率、超声心动图及血生化指标,观察疗效、不良反应。结果治疗后血压、心率改善,超声心动图示心脏结构及功能均有好转,心功改善1、2级,血生化无不良影响,未见严重不良反应。结论对CHF患者,在综合治疗基础上,给予氯沙坦钾50mg/d,吲达帕胺缓释片1.5mg/d,安全有效。

[Objective] To study the effect and safety of losartanK and indapamide SR for congestive heart failure （CHF）. [Methods] 59 CHF patients without shock, serious hepatic and renal insufficiency and hypokalemia, were given losartanK 50 mg/d, indapamide SR1.5 mg/d for 16 weeks, besides a routine treatment. The curative and side effect, the change of heart rate （HR）, blood pressure （BP）, echocardiography, biochemical criterion were observed. [Results] After 16 weeks of therapy, HR and BP, were improved in vary degrees. Echocardiography showed the heart structure and function were on the mend. Cardiac function （NYHA） improved 1-2 grade. We did not find adverse change in biochemical criterion or serious side effect. [Conclusion] LosartanK and indapamide SR to treat the CHF patients would be safe and effective.